3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Stomach Neoplasms
1
Psychological Well-Being
1
Pancreatic Neoplasms
1
Motor Activity
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyoma
1
Inflammation
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Agnosia
1
Abdominal Cancer
1
Interventions
Oxaliplatin
56
Capecitabine
49
Fluorouracil
37
Cisplatin
37
S 1 (combination)
23
Paclitaxel
18
Docetaxel
18
Leucovorin
16
pembrolizumab
13
Irinotecan
12
apatinib
11
titanium silicide
9
XELOX
9
Trastuzumab
9
Nivolumab
9
Hyperthermic Intraperitoneal Chemotherapy
8
Epirubicin
8
Drug Therapy
8
Tegafur
7
Radiotherapy
6
Neoadjuvant Therapy
6
gimeracil
5
Surgical Procedures, Operative
5
Gastrectomy
5
Chemotherapy, Adjuvant
5
tislelizumab
4
S-1 plus cisplatin
4
Ramucirumab
4
zolbetuximab
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Stomach Neoplasms
×
Tea
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled